Resumen Introducción: La hiponatremia se presenta en el 21,5-48% de los pacientes con síndrome de Guillaín-Barré (SGB), sin embargo, existe poca información sobre sus implicaciones clínicas en el SGB. Material y métodos: Se realizó un estudio observacional, transversal, de pacientes con diagnóstico de SGB. Recabamos información de variables clínicas, resultado del LCR y conducción nerviosa. Los pacientes con niveles de sodio < 135 meq/L en estudios de laboratorio al ingreso y antes del inicio de tratamiento fueron considerados con hiponatremia. Definimos buen pronóstico funcional a la presencia de marcha independiente (Hughes ≤ 2 puntos) a los 3 meses de seguimiento. Resultados: De 212 pacientes, 31 (14.6%) presentaron hiponatremia, sexo masculino 72%, edad promedio 45.9 ± 16 años, MRC score 30.1 ± 17 puntos, requerimiento de VMI 32%, presencia de disautonomía 32%. Recabamos ciento ochenta y dos estudios de conducción nerviosa y 165 resultados citoquímicos de punción lumbar. En el análisis comparativo entre los pacientes con hiponatremia vs sin hiponatremia, observamos diferencias significativas: edad (50.4 ± 14,9 vs. 43.8 ± 16.3, p = 0.03), días de hospitalización (mediana) (16 [IQR = 7-51] vs. 7 [IQR = 5-12] p = 0.03), disautonomía (54.8% vs. 28.2%, p = 0.006), niveles de proteínas (mgs/dL) en LCR (mediana) (105 [IQR = 59-165] vs. 39 [IQR = 28-57], p ≤ 0.001) y variante AIDP (70.4% vs. 42%, p = 0.011); En la recuperación de la marcha a los 3 meses, no hubo diferencia significativa (34,6% vs. 42,6%, p = 0.51). Conclusión: 14% de los pacientes con SGB presentan hiponatremia, con formas clínicas más severas, presencia de disautonomía, variante de AIDP más frecuente, niveles elevados de proteínas en LCR y mayor número de días de estancia hospitalaria, pero no afecta el pronóstico funcional.
Abstract Introduction: Hyponatremia occurs in 21-48% of patients with Guillain-Barre syndrome (GBS). However, little is known about the clinical implications in GBS. Materials and methods: In this observational, cross-sectional study, of patients diagnosed with GBS was conducted. Information used included: demographic clinical variables, cerebrospinal fluid (CSF) results, and nerve conduction studies. Patients with sodium levels < 135 meq/L in laboratory studies on admission and before treatment were considered to have hyponatremia. We defined good functional prognosis as the presence of independent gait (Hughes ≤ 2 points) at 3 months of follow-up. Results: Two hundred and twelve patients were initially screen and 31 (14.6%) presented hyponatremia; male gender was predominant with 72%, mean age was 45.9 ± 16 years, mean Modified Medical Research Council (MRC) score was 30.1 ± 17 points, invasive mechanical ventilation requirement was 32%, and the presence of dysautonomia 32%. One hundred and eighty-two nerve conduction studies, and 165 CSF cytochemical samples were collected. In the comparative analyses between the patients with hyponatremia versus without hyponatremia, we observed significant differences in mean age (50.4 ± 14.9 vs. 43.8 ± 16.3, p = 0.03), days of hospitalization (median) (16 [IQR = 7-51] vs. 7 [IQR = 5-12] p = 0.03), dysautonomia (54.8% vs. 28.2%, p = 0.006), protein levels (mgs/dL) in CSF (median) (105 [IQR = 59-165] vs. 39 [IQR = 28-57], p ≤ 0.001), and acute inflammatory demyelinating polyneuropathy (AIDP) variant (70.4% vs. 42%, p = 0.011). There was no significant finding in recovery of independent gait at 3 months (34.6% vs. 42.6%, p = 0.51). Conclusion: About 14% of patients with GBS presented with hyponatremia in our series and is associated with presence of dysautonomia, AIDP variant, elevated CSF protein levels and a greater number of days of hospital stay but did not impact functional prognosis.